|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we examined whether brain-derived neurotrophic factor (BDNF) and its receptor TrkB signaling plays a role in the risk for psychosis after exposure of cannabinoid (CB) receptor agonist during adolescence.
|
30629965 |
2019 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These findings provide evidence of the important role of early cannabis use and the Val66Met BDNF polymorphism on age at psychosis onset and they point out to sex-specific differences in cannabis use patterns.
|
28142064 |
2017 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Finally, we observe that frontal-cortex DNA methylation in the BDNF gene is correlated with genotype at a nearby nonsynonymous SNP that has been previously associated with major psychosis.
|
18319075 |
2008 |
|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain-derived neurotrophic factor (BDNF) is suggested to be a likely candidate biomarker for the diagnosis and treatment evaluation in psychosis.
|
31688384 |
2020 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To begin to address this issue, we conducted high-coverage targeted exome capture in a subset of neurotrophin genes in 48 comprehensively characterized cases with schizophrenia-related psychosis.
|
26215504 |
2015 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Brain derived neurotrophic factor (BDNF) is important for brain development and plasticity, and here we tested if the functional BDNF val66met variant modulates the association between high levels of childhood abuse, cognitive function, and brain abnormalities in psychoses.
|
23876786 |
2013 |
|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain-derived neurotrophic factor (BDNF) has been implicated in cognitive functions and in the pathogenesis of major psychoses.
|
16472361 |
2006 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome.
|
31822818 |
2019 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
There was no difference in the proportion of Met allele carriers between FEP patients and controls, and no significant influence of BDNF genotype on cognitive test scores in either of the psychosis groups.
|
23429848 |
2012 |
|
Psychotic Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Clinical, illness course and treatment factors might influence the variation of BDNF serum levels in patients with psychosis.
|
28550022 |
2017 |
|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Hippocampal volume and BDNF genotyping were obtained for 58 patients with first-episode psychosis and 39 healthy volunteers.
|
22192502 |
2012 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
COMT, D4 receptor, and BDNF polymorphisms are linked to methamphetamine abuse and psychosis.
|
19462300 |
2009 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This study aimed to investigate the degree of DNA methylation at the promoter region of the brain-derived neurotrophic factor (BDNF) gene, as one of the candidate genes associated with major psychoses, in peripheral blood mononuclear cells isolated from 94 patients with BD (BD I=49, BD II=45) and 52 healthy controls.
|
22353757 |
2012 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The present study aimed to explore possible effects of BDNF Val66Met polymorphism variations on progressive structural brain changes after 3 years from the first episode of psychosis.
|
23748016 |
2013 |
|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This study aimed to investigate the role of BDNF in MDMA-induced dependence and psychosis.
|
28472632 |
2017 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In this first phase of the project, the objective was to investigate the distribution of four candidate genetic polymorphisms for functional psychosis (Ser9Gly DRD3, 5HTTLPR, the VNTR 3'-UTR SLC6A3 and Val66Met BDNF) in a case-control sample.
|
19142409 |
2008 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No compelling evidence was found that BDNF genotype is associated with age at onset of psychotic disorder in the absence of cannabis use.
|
21305693 |
2011 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The results had adequate statistical power to suggest that BDNF Val66Met was not related to susceptibility to AD or the onset of AD, but that presence of one or two Met alleles of BDNF Val66Met polymorphism might present a risk factor for psychosis in AD.
|
21044653 |
2011 |
|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
A larger sample size, and evaluation of more single-nucleotide polymorphisms are needed to obtain more robust and conclusive findings regarding the relationship between the BDNF gene and psychosis.
|
17417060 |
2007 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A complex interplay between BDNF serum concentrations, personality traits, BDNF Val66Met polymorphism, and psychotic symptomatology has been arisen but further investigation is needed to better clarify the observed associations.
|
23333821 |
2013 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The Met allele of the functional polymorphism, BDNF Val66Met, is associated with psychotic disorders.
|
21728904 |
2012 |
|
Psychotic Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Multiple regression analysis revealed a significant positive association of plasma BDNF levels with planning ability across all groups.<b>Conclusions:</b> The lower peripheral BDNF levels in ARMS compared to FEP and CS might point towards an important drop of this neurotrophin prior to the onset of frank psychosis.
|
29938562 |
2019 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study.
|
14755448 |
2004 |
|
Psychotic Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, baseline levels of serum BDNF did not predict the development of psychosis (OR=0.64, CI = 0.40 - 1.02) or remission (OR=0.83, CI = 0.60 - 1.15) from UHR status.
|
29584866 |
2018 |
|
Psychotic Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Trend level gene-gender interaction effect for the BDNF rs6265 variant on age of onset of psychosis.
|
31445421 |
2019 |